COVI-VAC
COVI-VAC[edit | edit source]
COVI-VAC is a live attenuated vaccine developed for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus. It is designed to be administered intranasally, offering a needle-free vaccination option.
Development[edit | edit source]
COVI-VAC was developed by Codagenix Inc., a biotechnology company specializing in the development of vaccines using their proprietary deoptimization technology. The vaccine is designed to mimic the natural infection of the virus, thereby inducing a broad immune response.
Mechanism of Action[edit | edit source]
COVI-VAC is a live attenuated vaccine, meaning it contains a weakened form of the virus that is not capable of causing disease in healthy individuals. The vaccine is administered intranasally, which is intended to stimulate both systemic and mucosal immunity. This approach aims to provide a more comprehensive immune response compared to traditional intramuscular vaccines.
Clinical Trials[edit | edit source]
COVI-VAC has undergone several phases of clinical trials to evaluate its safety, immunogenicity, and efficacy.
Phase 1[edit | edit source]
The Phase 1 clinical trial was designed to assess the safety and tolerability of COVI-VAC in healthy adults. The trial also aimed to determine the optimal dose for further studies.
Phase 2[edit | edit source]
In the Phase 2 trial, the focus was on evaluating the immunogenicity of the vaccine, measuring the immune response generated in participants. This phase also continued to monitor safety and side effects.
Phase 3[edit | edit source]
The Phase 3 trial is a large-scale study to confirm the vaccine's efficacy in preventing COVID-19 in a diverse population. This phase involves thousands of participants and is critical for regulatory approval.
Advantages[edit | edit source]
- Needle-free administration: COVI-VAC is administered intranasally, which may increase vaccine acceptance among individuals with needle phobia.
- Broad immune response: As a live attenuated vaccine, COVI-VAC has the potential to induce both humoral and cellular immunity, as well as mucosal immunity.
- Ease of distribution: The intranasal delivery system may simplify logistics and distribution, especially in low-resource settings.
Challenges[edit | edit source]
- Cold chain requirements: Like many vaccines, COVI-VAC requires careful temperature control during storage and transport.
- Live virus concerns: Although attenuated, the use of a live virus may raise concerns about safety in immunocompromised individuals.
Regulatory Status[edit | edit source]
As of the latest updates, COVI-VAC is undergoing clinical trials and has not yet received emergency use authorization or full approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
